Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 88

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 88
---
13, 2025

F-3

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Balance Sheets

(Amounts in thousands, except share data and par value)

 December 31,December 31, 20242023Assets  Current assets:  Cash and cash equivalents$212,610 $76,911 Accounts receivable872 5,870 Unbilled receivables— 2,981 Prepaid expenses and other current assets3,144 4,967 Total current assets216,626 90,729 Non-current assets:Property and equipment, net9,912 2,113 Right-of-use asset, net5,535 10,068 In-process research and development assets150,600 150,600 Goodwill48,163 48,163 Long-term restricted cash1,669 1,377 Investments2,000 2,000 Other assets518 — Total assets$435,023 $305,050 Liabilities, convertible preferred stock, and stockholders’ deficit  Current liabilities:  Accounts payable$288 $3,150 Accrued expenses and other current liabilities12,076 15,572 Lease liability2,851 2,166 Deferred revenue— 2,311 Warrant liabilities— 720 Contingent value right liability7,761 15,983 Forward contract liabilities— 28,307 Total current liabilities22,976 68,209 Non-current liabilities:Lease liability, net of current portion11,133 8,789 Deferred revenue, net of current portion— 3,538 Warrant liabilities, net of current portion3,836 5,674 Contingent value right liability, net of current portion387,739 342,617 Deferred tax liabilities, net16,141 15,853 Total liabilities441,825 444,680 Commitments and contingencies (Note 19)Series A Preferred Stock, $0.0001 par value; no and 548,375 shares authorized as of December 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively— 296,851 Options for Series A Preferred Stock— 3